Nanoviricides (NNVC) Retained Earnings (2011 - 2026)
Nanoviricides (NNVC) posted Retained Earnings of -$154.8 million for Q1 2026, down 194.44% sequentially from $163.9 million in Q4 2025, and down 199.5% YoY from $155.6 million in Q1 2025.
Nanoviricides (NNVC) Retained Earnings (2011 - 2026) Analysis & Trends
Nanoviricides has reported Retained Earnings for 16 years, with the latest figure at -$154.8 million in Q1 2026.
- Quarterly Retained Earnings fell 199.5% year-over-year to -$154.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$154.8 million (down 199.5% YoY) and the FY2025 annual result came in at $156.4 million, up 212.19% from the prior year.
- Retained Earnings slipped to -$154.8 million in Q1 2026 per NNVC's latest filing, from $163.9 million in the prior quarter.
- Over five years, Retained Earnings peaked at $163.9 million in Q4 2025 and troughed at -$154.8 million in Q1 2026.
- A 5-year average of $29.7 million and a median of $145.6 million in 2022 frame the typical range for Retained Earnings.
- The sharpest annual moves came in 2022 and 2026: Retained Earnings jumped 229.51% in 2022, then sank 199.5% in 2026.
- Over 5 years, Retained Earnings stood at $145.7 million in 2022, then increased by 1.34% to $147.6 million in 2023, then slumped by 197.91% to -$144.5 million in 2024, then jumped by 213.42% to $163.9 million in 2025, then slumped by 194.44% to -$154.8 million in 2026.
- According to Business Quant data, Retained Earnings over the past three periods registered -$154.8 million, $163.9 million, and -$150.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.83 Bn | 130.98 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 85.79 Bn | 77.79 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 64.95 Bn | 59.77 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 58.59 Bn | 53.46 Bn | 52.00 Mn | 5.10 Bn |
| 5 | BeOne Medicines | 41.93 Bn | 36.83 Bn | 1.53 Bn | 13.05 Bn |
| 6 | Alnylam Pharmaceuticals | 31.52 Bn | 28.21 Bn | 992.69 Mn | -6.33 Bn |
| 7 | BioNTech SE | 27.98 Bn | 9.58 Bn | 668.28 Mn | 20.91 Bn |
| 8 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn | 6.57 Bn |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - | 4.38 Bn |
| 10 | Nanoviricides | 29.06 Mn | 25.85 Mn | - | 163.99 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -154.80 Mn |
| Dec 31, 2025 | 163.92 Mn |
| Sep 30, 2025 | -150.63 Mn |
| Jun 30, 2025 | 156.36 Mn |
| Mar 31, 2025 | 155.58 Mn |
| Dec 31, 2024 | -144.53 Mn |
| Sep 30, 2024 | -142.50 Mn |
| Jun 30, 2024 | -139.37 Mn |
| Mar 31, 2024 | -137.00 Mn |
| Dec 31, 2023 | 147.62 Mn |
| Sep 30, 2023 | 146.02 Mn |
| Jun 30, 2023 | 145.95 Mn |
| Mar 31, 2023 | 145.73 Mn |
| Dec 31, 2022 | 145.67 Mn |
| Sep 30, 2022 | -124.00 Mn |
| Jun 30, 2022 | 145.57 Mn |
| Mar 31, 2022 | 145.46 Mn |
| Dec 31, 2021 | 145.37 Mn |
| Sep 30, 2021 | 145.30 Mn |
| Jun 30, 2021 | 144.28 Mn |